Abstract
Anti PD-1/PDL-1 immune check point inhibitors (ICI) had dramatically changed the survival of patients with advanced non-small cell lung cancer (NSCLC). After platinum-based chemotherapy and ICI failure, taxane regimen remains standard of care. Some data have suggested an increased activity to chemotherapy received after ICI. Nevertheless, taxane appears to have modest effectiveness in pre-treated patients. We aimed to assess survival outcomes with taxane chemotherapies after ICI exposure and to identify prognostic and predictive factors that may influence response to those regimen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
